Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13884MR)

This product GTTS-WQ13884MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13884MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12961MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ12620MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ358MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ12262MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ399MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ11020MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ2206MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ15249MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW